{"filings":[{"id":2005801,"accession_number":"0001493152-26-035722","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2026-08-03T10:04:41+00:00","items":["5.07","9.01"],"status":"ready","headline":"Palatin shareholders elect directors, approve 260,000-share increase to stock plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected; Carl Spana and John Prendergast each received over 330,000 withheld votes.","Stockholders approved amendment to 2011 Stock Incentive Plan increasing shares by 260,000 (650,452 for, 28,736 against).","Ratification of KPMG as independent auditor for FY2026 passed with 982,584 votes for, 15,833 against.","Advisory vote on named executive officer compensation approved with 649,559 for, 28,732 against.","Broker non-votes of 319,687 on director elections and plan amendment; total votes present 54.3% of entitled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":501396,"accession_number":"0001493152-26-024219","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2026-05-18T21:07:52+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Palatin Technologies to transfer stock listing from NYSE American to Nasdaq Capital Market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntary withdrawal from NYSE American; last trade expected on NYSE May 28, 2026.","Common stock begins trading on Nasdaq Capital Market on May 29, 2026 under symbol PTN.","Nasdaq has approved the listing; no action required from existing stockholders.","CEO states move will improve visibility, trading liquidity, and institutional exposure.","Company continues to advance MC4R programs with IND for injectable agonist targeted for Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132238,"accession_number":"0001493152-25-028569","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K/A","filed_at":"2025-12-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Palatin board adopts annual say-on-pay vote after stockholder advisory approval","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders voted, on advisory basis, to hold say-on-pay vote every year at July 25, 2025 annual meeting.","Board determined to include annual advisory vote on executive compensation in proxy materials until next required frequency vote.","Amendment filed solely to disclose board's decision on frequency of future say-on-pay votes.","No other changes from original 8-K filed July 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132240,"accession_number":"0001654954-25-012928","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin closes $18.2M public offering, regains NYSE American listing compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed upsized public offering of 2,795,384 shares/pre-funded warrants and warrants at combined $6.50, gross proceeds $18.2M.","Regained compliance with NYSE American stockholders’ equity rule; trading resumed November 12, 2025 under symbol PTN.","Proceeds to support obesity program development and for working capital and general corporate purposes.","Offering included participation from CEO, CFO/COO, and certain board members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132239,"accession_number":"0001654954-25-012641","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Palatin prices $15.8M public offering; NYSE American listing resumes Nov 12","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced upsized public offering of 2.43M shares at $6.50/unit; gross proceeds ~$15.8M.","Series J warrants ($6.50) expire 31 days after FDA accepts IND for obesity program; Series K ($8.125) expire 5 years but terminate early if J not exercised.","Underwriters granted 45-day option for additional 364,615 shares; closing expected Nov 12, 2025.","Proceeds to fund obesity program and working capital; potential additional $15.8M upon cash exercise of Series J warrants.","NYSE American listing resumes Nov 12 under PTN; compliance regained after reverse split and $8.8M revenue from Boehringer Ingelheim."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148818,"accession_number":"0001654954-25-010973","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin earns €5.5M milestone payment from Boehringer Ingelheim in retinal disease collaboration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Achieved research milestone in collaboration with Boehringer Ingelheim, triggering €5.5M ($6.5M) payment to Palatin.","Collaboration, announced Aug 18, 2025, targets first-in-class melanocortin receptor treatment for diabetic retinopathy and diabetic macular edema.","Palatin eligible for up to €278M ($328M) in success-based milestones plus tiered royalties on net sales from the collaboration.","Upfront payment of €2M already received; total near-term research milestones of €18M including the €5.5M achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148817,"accession_number":"0001654954-25-010576","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Palatin begins OTCQB trading under PTNT after 1-for-50 reverse split; delisted from NYSE American","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["NYSE American suspended trading and initiated delisting on May 7, 2025, due to low stock price.","Reverse split 1-for-50 effective; shares traded under PTNTD for 20 days, then PTNT starting Sept 10, 2025.","Company now trades solely on OTCQB Market; no longer listed on NYSE American.","Stock previously traded on NYSE American under symbol PTN.","Delisting and reverse split reflect ongoing low-pricing and shareholder dilution concerns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148816,"accession_number":"0001654954-25-009743","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Palatin signs up to €280M collaboration with Boehringer for retinal disease therapies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["€2M upfront, up to €18M near-term milestones, up to €260M in regulatory/commercial milestones plus tiered royalties.","Collaboration focuses on melanocortin receptor agonists for diabetic retinopathy and DME; Boehringer funds two-year research.","Palatin assigned patent rights to Boehringer; potential first-in-class treatment targeting inflammation, vascular dysfunction, neurodegeneration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148812,"accession_number":"0001654954-25-009330","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K/A","filed_at":"2025-08-11T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Palatin Technologies to effect 1-for-50 reverse stock split on August 11, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective after market on August 11; split-adjusted trading on OTCQB begins August 12.","NYSE American delisted company on May 7 due to low selling price; stock now trades on OTCQB as PTNT.","FINRA approval delayed the reverse split; company expects approval after market August 11."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148815,"accession_number":"0001654954-25-009290","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Palatin Technologies announces 1-for-50 reverse stock split effective Aug 8, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split at 1-for-50 ratio effective 5:00 p.m. ET on August 8, 2025.","Common stock to trade on OTCQB Market (symbol PTNT) on a split-adjusted basis from Aug 11.","Ticker temporarily changes to PTNTD for 20 trading days post-split.","NYSE American delisted the stock on May 7, 2025 due to low selling price; now on OTCQB.","Stockholders receive cash for fractional shares; CUSIP changes to 696077 601."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148814,"accession_number":"0001654954-25-008579","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Palatin shareholders approve reverse stock split (1:50-1:100) and increase shares for equity awards","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split (1:50-1:100) approved; 12.4M for, 8.2M against. Board to set exact ratio.","Stockholders approved adding 3M shares to 2011 Stock Incentive Plan; 4.9M for, 3.2M against.","All four director nominees (Spana, Prendergast, Dunton, Morris) elected with ~7M votes each.","Issuance of shares upon exercise of Series B, D, and I warrants approved by stockholders.","Advisory vote favors annual say-on-pay frequency; executive compensation for FY2024 approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148813,"accession_number":"0001654954-25-007872","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"NYSE American Panel affirms delisting of Palatin Technologies; stock trades on OTCQB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Panel unanimously affirmed delisting under Sections 1003(a) and 1003(f)(v) due to low selling price of common stock.","NYSE American suspended trading on May 7, 2025; stock has traded on OTCQB under symbol PTNT since June 9, 2025.","Company intends to appeal Panel decision to the full Committee for Review; appeal hearing expected in late August or September 2025.","Company is actively working to resolve listing deficiencies prior to the appeal hearing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167694,"accession_number":"0001654954-25-006936","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["1.01","5.03","3.02","9.01"],"status":"ready","headline":"Palatin Technologies delisted from NYSE American; raises $340K in insider private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NYSE American commenced delisting proceedings; common stock suspended May 7, 2025. Now trades on OTCQB under PTNT.","On June 10, 2025, entered private placement with CEO, CFO, and two directors for $340,000 gross proceeds.","Issued Series D Preferred Stock convertible at $0.11/share and warrants exercisable at $0.11, subject to stockholder approval.","Proceeds to be used for general working capital purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167693,"accession_number":"0001654954-25-005296","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["1.01","3.01","8.01","9.01"],"status":"ready","headline":"Palatin Technologies delisted from NYSE American; reduced offering raises only $1.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NYSE American suspended trading and commenced delisting proceedings due to low stock price; shares transitioned to OTC Pink under 'PTNT'.","Original $11.5M offering (76,666,667 shares at $0.15) collapsed after delisting; net proceeds fell to $1.1M.","Offering included Series F, G, H warrants with exercise prices $0.30, $0.15, $0.225; potential additional $11.5M from warrant exercise is uncertain.","Company intends to appeal delisting by May 14, 2025 but no assurance of success; CEO states commitment to business plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167692,"accession_number":"0001654954-25-004125","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Palatin Technologies receives NYSE American delisting notice; intends to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE Regulation determined to delist PTN for failure to comply with stockholders' equity requirements (Sections 1003(a)(i)-(iii)).","Maximum 18-month compliance plan ended April 10, 2025; Company unable to demonstrate regained compliance.","Company intends to appeal to Listings Qualifications Panel; appeal deadline is April 25, 2025.","Common stock expected to continue trading on NYSE American pending appeal outcome.","No assurance of regaining compliance before the Panel hearing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184973,"accession_number":"0001654954-25-003600","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin reports positive Phase 2 topline results for UC drug PL8177 and obesity combo study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["UC Phase 2: Clinical remission 33% PL8177 vs 0% placebo; clinical response 78% vs 33% (p<0.005) after 8 weeks.","Obesity Phase 2: Co-admin bremelanotide + tirzepatide met primary endpoint with 4.4% weight loss vs 1.6% placebo (p<0.0001).","Obesity: 40% of co-admin group achieved 5% weight loss (p<0.05); low-dose bremelanotide stopped weight regain post-tirzepatide.","Next-gen MC4R long-acting peptides and oral small molecules; IND applications planned for 4Q25, clinical data 1H26.","Licensing discussions for UC program advancing with multiple big pharma companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184972,"accession_number":"0001654954-25-001362","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Palatin enters $6M ATM equity distribution agreement with A.G.P.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At-the-market offering of up to $6.0M of common stock via A.G.P./Alliance Global Partners.","Sales at market prices on NYSE American; commission of 3.0% of gross proceeds.","Offering made under existing S-3 registration statement; prospectus supplement filed Feb 11, 2025.","Company not obligated to sell any shares; can suspend solicitation at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184971,"accession_number":"0001654954-25-001286","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Palatin Technologies announces $4.7M equity offering at $1.00/share, private warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.7M from sale of 2.55M shares at $1.00/share and pre-funded warrants for 2.138M shares.","Private placement includes warrants to purchase 4.688M shares at $1.00, exercisable starting 6 months after issuance for 5.5 years.","Net proceeds will be used for general working capital and corporate purposes.","A.G.P./Alliance Global Partners leads placement; Laidlaw & Co. co-placement agent; 7% cash fee paid.","Company subject to 45-day lockup on additional equity sales and 6-month ban on variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201572,"accession_number":"0001654954-24-015560","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Palatin receives ~$3.4M from warrant exercise; issues new Series C/D warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$3.4M from exercise of 3,907,679 shares at amended price $0.875.","Issued unregistered Series C warrants for 3,907,679 shares and Series D for 1,953,839 shares, both at $0.875/share.","Series C warrants exercisable immediately, 5-year term; Series D exercisable after stockholder approval, 5-year term.","Transaction expected to close Dec 17, 2024; proceeds for working capital and general corporate purposes.","Company agreed to file resale registration statement for inducement warrant shares by Feb 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201571,"accession_number":"0001654954-24-014334","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Palatin Q1 net loss $7.8M; obesity focus with BMT-801 topline Q1 2025; strategic review for non-obesity assets","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.8M ($0.39/share) vs $5.2M a year ago; cash $2.4M at Sep 30, plus $2.5M deferred payment from Vyleesi sale received Nov 2024.","Phase 2 BMT-801 (bremelanotide+tirzepatide) obesity study fully enrolled; topline results expected Q1 2025.","Investment bank retained to explore strategic options for non-obesity programs including DED, UC, glaucoma, retina, and male ED.","Novel MC4R long-acting peptide and oral small molecule IND enabling starts Q1 2025; Phase 1 targeted Q4 2025.","DED program: FDA Type C meeting concluded; subject to funding, Phase 3 enrollment could start Q1 2025."],"consensus_eps_estimate":-1.2558,"consensus_eps_actual":-19.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201570,"accession_number":"0001654954-24-012756","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Palatin receives NYSE American delisting notice for equity deficiency; cure period extended to April 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE American notified Palatin of non-compliance with Section 1003(a)(iii) requiring stockholders' equity of at least $6M after five consecutive years of losses.","Palatin was already non-compliant under Sections 1003(a)(i) and (ii); the new notice adds a third deficiency.","The Exchange accepted Palatin's compliance plan and granted a cure period through April 10, 2025, with quarterly monitoring.","The notice has no immediate effect on trading of PTN common stock, but failure to regain compliance could lead to delisting.","Palatin is exploring multiple funding avenues to achieve compliance and plans future transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201569,"accession_number":"0001654954-24-012549","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Palatin reports FY2024 net loss $29.7M, cash $9.5M; outlines clinical milestones for obesity, DED, ED, UC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2024 $29.7M ($2.02 per share) vs $24.0M ($2.21) prior year; revenue declined as Vyleesi asset sold.","Cash and cash equivalents $9.5M at June 30, 2024; auditor includes going concern explanatory paragraph.","Obesity Phase 2 MC4R+GLP-1 trial enrollment to complete early Q4 2024; topline results expected Q1 2025.","DED Phase 3 MELODY-2/3 trials to start enrollment Q1 2025; topline results anticipated Q4 2025.","Diabetic nephropathy Phase 2 BREAKOUT topline results expected Q4 2024; UC Phase 2 interim readout Q4 2024."],"consensus_eps_estimate":-1.2558,"consensus_eps_actual":-19.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217578,"accession_number":"0001654954-24-011592","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Palatin sets Dec 12, 2024 annual meeting; proxy deadlines announced","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting set for December 12, 2024; record date October 28, 2024.","Rule 14a-8 shareholder proposal deadline: October 21, 2024.","Bylaw director nominations and other proposals due by September 13, 2024.","Meeting date is >30 days from prior year's meeting, triggering extended deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237453,"accession_number":"0001654954-24-008320","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Palatin shareholders elect all seven directors, approve equity plan share increase and say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven directors elected: Carl Spana, John Prendergast, Robert deVeer, J. Stanley Hull, Alan Dunton, Arlene Morris, Anthony Manning.","Amendment to 2011 Stock Incentive Plan approved, increasing share pool by 1,000,000 shares.","KPMG ratified as independent auditor for FY2024 with 6.73M votes for.","Advisory vote on executive compensation (say-on-pay) approved with 925K for, 665K against.","Broker non-votes totaled 5,280,762 on director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237452,"accession_number":"0001654954-24-008011","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Palatin Technologies raises ~$6.1M via warrant inducement with institutional investor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters inducement letter; institutional investor exercises existing warrants for $6.1M gross proceeds.","Existing warrants covering 3,233,277 shares exercised at reduced exercise price of $1.88/share.","Company issues new Series A warrants (2,727,273 shares) and Series B warrants (2,122,642 shares) at $1.88 exercise price, five-year term.","Closing expected June 24, 2024; net proceeds for working capital and corporate purposes.","Issuance of 1,624,201 Series B warrant shares subject to stockholder approval under NYSE American rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237451,"accession_number":"0001654954-24-006304","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Palatin Q3 net loss $8.4M; Phase 3 DED study meets pain endpoint, 7 of 11 secondary endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 MELODY-1 for PL9643 in dry eye disease met co-primary pain endpoint (P<0.025) and 7 of 11 secondary endpoints at 12 weeks; rapid onset at 2 weeks.","No revenue in Q3 (Vyleesi rights sold Dec 2023); net loss $8.4M ($0.53 loss per share) vs $8.7M ($0.76) a year ago.","Cash and equivalents $10.0M as of March 31, 2024; expects to fund operations into 2H calendar 2024; raised $10M in registered direct offering in Jan 2024.","Obesity: Phase 2 trial of MCR4 agonist + GLP-1 targeted to start Q2 2024 with topline data in 2H 2024.","Male ED: Phase 2 trial of bremelanotide + PDE5i in non-responders targeted to start Q2 2024, topline expected 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":4140090.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254994,"accession_number":"0001654954-24-001811","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Palatin Q2 FY2024 net loss $7.8M; Vyleesi sale closed; pipeline catalysts ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.8M ($0.56/share) vs net income of $2.7M ($0.25) in Q2 FY2023.","Vyleesi net product revenue $2.0M (+98% YoY); completed asset sale to Cosette for up to $171M ($12M upfront).","Cash $9.5M + $2.3M AR at Dec 31, 2023; added $9.2M net from Feb 2024 equity offering.","PL9643 Phase 3 dry eye disease topline data expected Feb 2024; PL8177 UC interim analysis Q2 2024.","Phase 2 obesity (MCR4+GLP-1) and ED (bremelanotide+PDE5i) studies to start 1H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":4140090.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254993,"accession_number":"0001654954-24-001212","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Palatin closes $10M registered direct offering; details Vyleesi sale to Cosette with $12M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered direct offering closed Feb 1: 1,831,503 shares at $5.46, gross $10M, net proceeds ~$9.2M.","Warrants for 1,831,503 shares at $5.46, exercisable after 6 months for 4 years; placement agent warrants 91,575 at $6.825.","Vyleesi sale to Cosette closed Dec 20: $12M upfront ($9.5M at close, $2.5M in 12 months), up to $159M sales milestones.","Regulatory milestones up to $10.5M from Fosun (China) and Kwangdong (S. Korea) associated with Vyleesi licensing.","Net proceeds for working capital; Vyleesi divestiture refocuses pipeline on melanocortin receptor modulators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272469,"accession_number":"0001654954-23-015795","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["1.01","2.01","8.01","9.01"],"status":"ready","headline":"Palatin sells Vyleesi rights to Cosette for up to $171M; $12M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up-front payment of $12M plus sales-based milestones up to $159M based on annual net sales of $15M to $200M.","Additional regulatory milestones of $10.5M from prior licenses (Fosun $7.5M, Kwangdong $3.0M) remain receivable.","Palatin will provide transitional services; operational separation ensures continued patient access for Vyleesi.","Company shifts focus to melanocortin pipeline: Phase 3 dry eye (PL9643) topline data expected soon; Phase 2 ulcerative colitis (PL8177) interim Q1 2024.","Transaction closed simultaneously with signing on December 19, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272468,"accession_number":"0001654954-23-015715","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"NYSE American accepts Palatin's plan to regain listing compliance; deadline April 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity fell below $2M (Section 1003(a)(i)) and $4M (1003(a)(ii)) due to net losses.","Plan accepted Dec 13, 2023; compliance must be regained by April 10, 2025.","If Palatin fails to meet milestones or the final deadline, delisting proceedings may begin.","Company is exploring multiple funding avenues to boost equity and meet Exchange requirements.","No immediate impact on PTN trading; stock remains listed on NYSE American."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272467,"accession_number":"0001654954-23-014239","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Palatin Q1 FY2024 net loss narrows to $5.9M; Vyleesi revenue up 142% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $(0.48) vs $(0.86) YoY; Vyleesi net revenue $2.1M, +142% YoY.","Phase 3 DED study (PL9643) fully enrolled (n=570); topline data expected late Q4 2023.","Phase 2 oral PL8177 in ulcerative colitis interim analysis targeted Q1 2024.","Vyleesi gross sales $4.6M (+11% vs prior quarter); 7th consecutive quarter double-digit growth.","Cash $5.5M at Sept 30; plus $4.5M net from October offering; expects cash into H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":2105977.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272466,"accession_number":"0001654954-23-013343","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Palatin Technologies raises $5M in registered direct offering and private placement of warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,325,000 shares and pre-funded warrants for 1,033,491 shares at $2.12/unit; private warrants for 2,358,491 shares at $2.12 exercise price.","Gross proceeds $5M; net proceeds $4.5M after placement agent fees and expenses for general corporate purposes.","Offering closed Oct 24, 2023; H.C. Wainwright received 7% cash fee and 117,925 placement agent warrants at $2.65.","60-day lock-up on share issuance and 12-month restriction on variable rate transactions are in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272465,"accession_number":"0001654954-23-013131","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-10-19T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Palatin prelim Q1: Vyleesi gross revenue $4.6M, net $2.1M, up 100% and 137% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Gross product revenue $4.6M (+11% qoq, +100% YoY); net product revenue $2.1M (+18% qoq, +137% YoY).","Prescriptions dispensed grew 14% over prior quarter and 88% over comparable quarter last year.","Seventh consecutive quarter of double-digit growth in product revenue and prescriptions dispensed.","CEO reports net revenue per prescription improving; net product revenue exceeds Vyleesi quarterly operating expenses.","All key metrics (new patient starts, refill rates, insurance reimbursement, new prescribers) showed positive trends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":2105977.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272464,"accession_number":"0001654954-23-012913","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Palatin receives NYSE American non-compliance notice for insufficient stockholders' equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received NYSE American notice on Oct 10, 2023; stockholders' equity below $2M and $4M thresholds.","Must submit compliance plan by Nov 9, 2023; must regain compliance by April 10, 2025.","No immediate effect on trading of PTN common stock; business and SEC reporting unaffected.","Company is assessing funding avenues to achieve compliance, including potential transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289306,"accession_number":"0001654954-23-012336","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Palatin reports FY2023 net loss $27.5M; Vyleesi net revenue up 298%; PL9643 fully enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.5M ($2.53 diluted EPS) for FY2023 vs $36.2M loss ($3.79 EPS) in FY2022.","Vyleesi net product revenue $4.9M in FY2023, up 298% YoY; Q4 net revenue $1.8M, up 128%.","Phase 3 PL9643 (dry eye) fully enrolled (570 patients); topline data expected late Q4 2023.","Phase 2 PL8177 (ulcerative colitis) interim analysis targeted Q1 2024; topline H1 2024.","Cash $11.0M plus $2.9M receivables as of June 30; audit includes going concern paragraph."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289305,"accession_number":"0001654954-23-011672","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin to present at H.C. Wainwright investment conference on Sept 13","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Palatin management will present at the H.C. Wainwright 25th Annual Global Investment Conference.","Presentation is scheduled for Wednesday, September 13, 2023 at 10:00 a.m. ET.","Live webcast available on Palatin's website; replay accessible for 30 days.","Conference takes place September 11-13, 2023 in New York, NY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289304,"accession_number":"0001654954-23-011637","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin completes enrollment in Phase 3 dry eye study (PL9643); 570 patients enrolled, topline expected Q4 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PL9643 MELODY-1 Phase 3 study enrolled 570 patients with moderate-to-severe dry eye disease.","Topline data anticipated by end of Q4 2023; interim analysis of first 120 patients showed safety and efficacy.","Assuming positive results, NDA submission to FDA expected mid-2025 after two more Phase 3 studies in 2024-2025.","Company highlighted PL9643's novel mechanism of action and differentiated profile vs. current DED treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289303,"accession_number":"0001654954-23-010419","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin initiates Phase 2 study of bremelanotide/PDE5i combo for ED non-responders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approximately 30–40% of ED patients do not respond to PDE5i monotherapy.","Phase 2 trial of bremelanotide co-formulated with a PDE5i expected to start Q4 2023.","Published data show synergy between bremelanotide and PDE5i via distinct mechanisms.","Bremelanotide is the active agent in Vyleesi, approved for HSDD in women.","Palatin successfully co-formulated bremelanotide with a PDE5i for single injection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289302,"accession_number":"0001654954-23-010239","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin: Fosun reports first Vyleesi sale in China; Kwangdong completes Phase 3 enrollment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fosun dispensed first Vyleesi prescription in Hainan Province, China.","Kwangdong completed Phase 3 enrollment: 193 patients enrolled, 180 completed (93%).","Data from Korea trial expected by year end; potential MFDS submission in H1 2024.","Palatin eligible for up to $92.5M in milestones from Fosun plus royalties; $3M milestone from Kwangdong.","Vyleesi is only FDA-approved as-needed HSDD treatment; Palatin reported six consecutive quarters of double-digit prescription growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289301,"accession_number":"0001654954-23-010188","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin partners with UpScriptHealth to expand Vyleesi access via telehealth platform","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Palatin (PTN) entered strategic partnership with telemedicine company UpScriptHealth.","Vyleesi, the first FDA-approved as-needed HSDD treatment, will be on UpScriptHealth's Women's Telehealth Platform.","UpScriptHealth's patient base is hundreds of thousands of women; partnership aims to boost HSDD awareness.","Palatin CEO Carl Spana said the deal fortifies existing telehealth programs and expands patient access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289300,"accession_number":"0001654954-23-010120","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin to present at Canaccord Genuity Growth Conference on Aug 9","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Management to participate in Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023.","Fireside chat scheduled at 5:00 p.m. ET in Boston, MA.","Live webcast available on Palatin's investor relations website; replay for 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289299,"accession_number":"0001654954-23-009002","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin prelim Q4 Vyleesi net revenue $1.7M, up 122% YoY; prescriptions +89% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Gross product revenue $4.1M, up 20% QoQ and 78% YoY.","Net product revenue $1.7M, up 42% QoQ and 122% YoY.","Prescriptions dispensed increased 14% QoQ and 89% YoY.","New healthcare prescribers up 20% QoQ; 6 consecutive quarters of double-digit growth.","Management states net revenue per prescription continues to improve, exceeding quarterly operating expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":4853678.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310092,"accession_number":"0001654954-23-008230","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Palatin shareholders approve all four proposals at 2023 annual meeting; equity plan share increase passes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; broker non-votes 2,999,632 for each director.","Ratification of KPMG as independent auditor approved: 4,575,827 for, 378,813 against.","Amendment to 2011 Stock Incentive Plan adding 1,000,000 shares approved: 1,312,262 for, 634,396 against.","Say-on-pay advisory vote for named executive officers passed: 1,332,202 for, 634,396 against, 18,140 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310091,"accession_number":"0001654954-23-007322","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin presents preclinical data on PL8177 in diabetic nephropathy; Phase 2 BREAKOUT study enrolling","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PL8177 preserved podocyte count and WT1 expression in diabetic rats vs. vehicle.","Glomerular hypertrophy trended toward reduction in PL8177-treated kidneys.","Data presented at International Podocyte Conference, May 24-26, 2023 in Philadelphia.","Phase 2 BREAKOUT study (bremelanotide) for diabetic kidney disease now enrolling (NCT05709444).","CEO cites melanocortin system potential for new inflammatory disease treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310090,"accession_number":"0001654954-23-006648","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Palatin Q3 FY2023 net loss $7.1M; Vyleesi revenue up 453% YoY; Phase 3 dry eye data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.1M ($0.63/share) vs $7.6M ($0.80) prior year; operating expenses $8.5M.","Vyleesi net product revenue $1.2M (+16% QoQ, +453% YoY); gross sales $3.4M (+165% YoY).","Phase 3 PL9643 dry eye lead-in (120 pts) showed statistical separation on signs/symptoms; final data expected H2 2023.","Cash $19.6M plus $1.7M receivables; expects to fund operations through CY2023.","Received $4.7M non-dilutive funding from NJ Economic Development Authority."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3091745.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310089,"accession_number":"0001654954-23-006269","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin to report Q3 FY2023 results on May 16; conference call set for 11:00 a.m. ET","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Results press release due before market open on Tuesday, May 16, 2023.","Conference call and webcast scheduled for 11:00 a.m. ET on May 16.","Call dial-in: US toll-free 1-888-506-0062, international 1-973-528-0011, access code 555988.","Replay available May 16-30 via toll-free 1-877-481-4010 (code 48459)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310088,"accession_number":"0001654954-23-005946","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin updates on PL9643 dry eye Phase 3 lead-in data and PL8177 UC data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PL9643 lead-in data from MELODY-1 Phase 3 shows excellent ocular tolerability and broad efficacy on dry eye signs/symptoms.","PL8177 preclinical data in rat UC models reduces colonic damage; oral formulation delivers to colon without systemic absorption.","Phase 2 study PL8177-205 for UC enrolling; interim and topline data expected in 2H2023.","KOL webinar replay with Dr. Stouch, Ousler, Raizman available on Palatin website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310087,"accession_number":"0001654954-23-005504","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin to host KOL webinar on PL9643 Phase 3 dry eye data on May 8, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Webinar to review positive PL9643 Phase 3 MELODY-1 Lead-In population data for moderate to severe dry eye disease.","Final PL9643 Phase 3 MELODY-1 data expected in H2 2023; trial enrollment continuing.","Webinar moderated by CEO Carl Spana; featuring KOLs Dr. Stouch, Mr. Ousler, and CMO Dr. Raizman.","Company cites PL9643 positive effects on both signs and symptoms of dry eye disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310086,"accession_number":"0001654954-23-005253","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin reports positive initial Phase 3 data for PL9643 dry eye drug at ARVO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PL9643 showed statistically significant improvement on multiple sign and symptom endpoints in Phase 2 and Phase 3 lead-in data.","No ocular adverse events or discontinuations due to tolerability; excellent safety profile.","MELODY-1 Phase 3 study continues; topline data expected in second half of 2023.","Data presented at ARVO 2023; magnitude of difference vs vehicle exceeds reported for approved products for several endpoints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310085,"accession_number":"0001654954-23-005136","cik":911216,"company_name":"PALATIN TECHNOLOGIES INC","ticker":"PTN","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palatin presents preclinical data for PL9588 glaucoma candidate at ARVO; shows IOP reduction in rabbits","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Topically administered PL9588 reduced intraocular pressure (IOP) in normotensive rabbits.","IOP reduction magnitude similar or greater than FDA-approved drugs latanoprost and timolol.","Single topical dose of PL9588 lowered IOP for 24 hours.","PL9588 is a melanocortin agonist; data supports continued development for once-daily glaucoma treatment.","Company plans to move into clinical development pending available resources."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26119757.635167874,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-04-25T23:59:59+00:00|310085"}